Ramzey J. Abujarour, Ph.D.
Affiliations: | 2005 | University of Texas at Dallas, Richardson, TX, United States |
Area:
Cell Biology, Microbiology BiologyGoogle:
"Ramzey Abujarour"Parents
Sign in to add mentor| Rockford K. Draper | grad student | 2005 | UT Dallas | |
| (Protein toxins in membrane trafficking.) | ||||
| Sheng Ding | post-doc | Scripps Institute (Chemistry Tree) | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| van der Stegen SJC, Lindenbergh PL, Petrovic RM, et al. (2024) Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering |
| Hammer Q, Perica K, van Ooijen H, et al. (2023) Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells. Biorxiv : the Preprint Server For Biology |
| Cichocki F, Bjordahl R, Goodridge JP, et al. (2022) Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nature Communications. 13: 7341 |
| van der Stegen SJC, Lindenbergh PL, Petrovic RM, et al. (2022) Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering |
| Woan KV, Kim H, Bjordahl R, et al. (2021) Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell |
| Mandal M, Clarke R, Stegen Svd, et al. (2020) Abstract 3245: FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies Immunology |
| Zhu H, Blum R, Bjordahl R, et al. (2019) Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity. Blood |
| Bjordahl R, Gaidarova S, Goodridge JP, et al. (2019) FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma Blood. 134: 3214-3214 |
| Chang C, Van Der Stegen S, Mili M, et al. (2019) FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial Blood. 134: 4434-4434 |
| Abujarour R, Lai Y, Pribadi M, et al. (2019) Abstract LB-073: Generation of novel single cell-derived engineered master pluripotent cell line as a renewable source for off-the-shelf TCR-less CAR T cells in support of first-of-kind clinical trial Cancer Research. 79 |